BeOne Medicines (ONC) Assets Average (2016 - 2026)
BeOne Medicines (ONC) posted quarterly Assets Average of $8.4 billion for Q1 2026, up 42.34% year-over-year from $5.9 billion in Q1 2025, and up 5.82% quarter-over-quarter from $7.9 billion in Q4 2025.
BeOne Medicines (ONC) Assets Average (2016 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Assets Average for 11 consecutive years, with $8.4 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 42.34% year-over-year to $8.4 billion; the TTM figure through Mar 2026 stood at $8.4 billion (up 42.34% YoY), while the FY2025 annual figure was $7.1 billion, up 20.32% from the prior year.
- Assets Average rose to $8.4 billion in Q1 2026 per ONC's latest filing, from $7.9 billion in the prior quarter.
- Across five years, Assets Average topped out at $8.4 billion in Q1 2026 and bottomed at $5.6 billion in Q3 2023.
- Historically, Assets Average has averaged $6.5 billion across 5 years, with a median of $5.9 billion in 2025.
- Annual changes were most pronounced in 2022 — Assets Average soared 44.96% — and 2023, when it slumped 30.92%.
- BeOne Medicines' Assets Average stood at $6.1 billion in 2022, then fell by 7.18% to $5.7 billion in 2023, then gained by 3.72% to $5.9 billion in 2024, then jumped by 34.63% to $7.9 billion in 2025, then gained by 5.82% to $8.4 billion in 2026.
- Business Quant data shows ONC's Assets Average at $8.4 billion in Q1 2026, $7.9 billion in Q4 2025, and $7.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.86 Bn |
| Mar 31, 2026 | 8.37 Bn |
| Dec 31, 2025 | 7.91 Bn |
| Sep 30, 2025 | 6.97 Bn |
| Jun 30, 2025 | 6.07 Bn |
| Mar 31, 2025 | 5.88 Bn |
| Dec 31, 2024 | 5.88 Bn |
| Sep 30, 2024 | 5.77 Bn |
| Jun 30, 2024 | 5.69 Bn |
| Mar 31, 2024 | 5.74 Bn |
| Dec 31, 2023 | 5.67 Bn |
| Sep 30, 2023 | 5.63 Bn |
| Jun 30, 2023 | 5.84 Bn |
| Mar 31, 2023 | 5.72 Bn |
| Dec 31, 2022 | 6.10 Bn |
| Sep 30, 2022 | 7.05 Bn |
| Jun 30, 2022 | 7.70 Bn |
| Mar 31, 2022 | 8.28 Bn |
| Dec 31, 2021 | 6.91 Bn |
| Sep 30, 2021 | 5.41 Bn |